May 31, 2017 13:33 pm UTC| Business
ORLANDO, Fla., May 31, 2017 -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of...
May 31, 2017 13:33 pm UTC| Business
ORLANDO, Fla., May 31, 2017 -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of...
May 31, 2017 13:33 pm UTC| Business
ORLANDO, Fla., May 31, 2017 -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of...
May 31, 2017 13:33 pm UTC| Business
ORLANDO, Fla., May 31, 2017 -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of...
May 31, 2017 13:33 pm UTC| Business
ORLANDO, Fla., May 31, 2017 -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of...
May 31, 2017 13:33 pm UTC| Business
ORLANDO, Fla., May 31, 2017 -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of...
May 31, 2017 13:33 pm UTC| Business
ORLANDO, Fla., May 31, 2017 -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of...